ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Collagen remodeling in breast cancer progression: from molecular mechanisms to diagnostic and therapeutic opportunities.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collagen remodeling is an emerging hallmark of breast cancer progression, offering profound insights into tumor biology and therapeutic vulnerability. While breast cancer has long been understood through the lens of genetic mutations and cellular deregulation, recent advances have emphasized the crucial role of the tumor microenvironment (TME), particularly the extracellular matrix (ECM), in directing cancer progression. As the most prevalent structural protein within the ECM, collagen plays a key role in tissue mechanics, cell signaling, and immune regulation. This review examines the current understanding of the molecular configuration and diversity of collagen types found in breast tissue, with an emphasis on the pathological alterations that occur during malignant transformation. We explore how enzymes, such as matrix metalloproteinases (MMPs) and lysyl oxidase (LOX), regulate collagen degradation and crosslinking. These processes drive ECM stiffening and the formation of aligned collagen fibers, which promote tumor invasion, angiogenesis, and immune evasion. This article also highlights tumor-associated collagen signatures (TACS) as potential diagnostic biomarkers and evaluates advanced imaging modalities, including techniques like second harmonic generation (SHG) microscopy and magnetic resonance elastography (MRE), which enable in vivo assessment of collagen remodeling. Furthermore, we review therapeutic approaches targeting collagen-modifying enzymes and emerging nanoparticle-based delivery systems designed to disrupt the fibrotic ECM and improve drug penetration. Ultimately, collagen is now recognized not merely as a structural scaffold, but as an influential factor actively involved in the progression of breast cancer. Understanding the mechanisms and clinical implications of collagen remodeling may open novel paths for personalized diagnostics and targeted therapies, offering new hope for the management of aggressive and treatment-resistant breast cancers.
Indexed as
Identifiers
42301607What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.